Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol

INTRODUCTION: Current clinical guidelines recommend systematic antitumour therapy as the primary treatment option for patients with stage IIIb hepatocellular carcinoma (HCC) based on the China liver cancer (CNLC) staging criteria. Several different targeted therapeutics have been applied in combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jun Tao, Zhong, Jian-Hong, Zhang, Jie, Gong, Wen Feng, Ma, Liang, Li, Le Qun, Xiang, Bang-De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546157/
https://www.ncbi.nlm.nih.gov/pubmed/37770273
http://dx.doi.org/10.1136/bmjopen-2022-067730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546157/
https://www.ncbi.nlm.nih.gov/pubmed/37770273
http://dx.doi.org/10.1136/bmjopen-2022-067730

Ejemplares similares